Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Cidara Therapeutics, Inc. (NASDAQ: CDTX) reported Q3 2021 results, showing revenues of $7.1 million for the quarter, up from $2.4 million in Q3 2020, primarily due to a collaboration with Janssen Pharmaceuticals. Net losses for Q3 2021 were $18.1 million, compared to $17.6 million in Q3 2020. The company raised $38.5 million in equity from public offerings to extend its cash runway. Cidara plans to report top-line data from its ReSTORE Phase 3 trial by year-end 2021 and anticipates filing an NDA for its drug rezafungin in mid-2022.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has successfully completed its public offerings, raising approximately $38.5 million. This includes 17,064,511 shares of common stock priced at $1.55 per share and 774,194 shares of Series X Convertible Preferred Stock at $15.50 per share. The offerings were managed by Cantor Fitzgerald & Co. and others under an effective SEC shelf registration. The funds will support the development of long-acting therapeutics targeting serious diseases, enhancing patient care through innovative treatments.
Cidara Therapeutics announced the pricing of concurrent public offerings totaling approximately $35.0 million. The offerings consist of 14,838,706 shares of common stock priced at $1.55 per share and 774,194 shares of Series X Convertible Preferred Stock priced at $15.50 per share. Underwriters have a 30-day option to purchase an additional 2,225,805 shares of common stock. The offerings are expected to close around October 13, 2021, subject to customary conditions. Cantor Fitzgerald & Co. is the sole book-running manager.
Cidara Therapeutics (Nasdaq: CDTX) has launched concurrent underwritten public offerings for its common stock and Series X Convertible Preferred Stock. The common stock offering includes a 30-day option for underwriters to purchase additional shares at the offering price. The completion of these offerings is not contingent upon one another and is subject to market conditions. Cantor Fitzgerald & Co. serves as the sole book-running manager for these offerings. The securities are offered under a shelf registration statement with no assurance on the terms or timing of completion.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced on October 1, 2021, that its Compensation Committee granted stock options and restricted stock units totaling 169,000 shares to ten new employees. The options have an exercise price of $2.24 per share, equal to the stock's closing price on the grant date. Vesting occurs over four years, with 25% vesting after one year. This initiative is part of the company's 2020 Inducement Incentive Plan and is compliant with Nasdaq Listing Rule 5635(c)(4). Cidara focuses on long-acting therapeutics for serious diseases, including its lead candidate, rezafungin acetate.
Cidara Therapeutics (NASDAQ: CDTX) will present new clinical data at the 10th Congress on Trends in Medical Mycology (TIMM) from October 8-11, 2021, in Aberdeen, Scotland. The focus is on rezafungin, a once-weekly echinocandin in Phase 3 trials for serious fungal infections. Top-line data from the Phase 3 ReSTORE trial is expected by the end of 2021, with a New Drug Application (NDA) anticipated in mid-2022. Key presentations include safety and pharmacokinetics in hepatic impairment and post-antifungal effects against various Candida species.
Cidara Therapeutics (NASDAQ: CDTX) announced its participation in IDWeek from September 29 to October 3, 2021, where it will present new data on rezafungin, a novel once-weekly echinocandin in Phase 3 trials for serious fungal infections. The presentations will cover clinical safety in patients with hepatic impairment and the efficacy of rezafungin against invasive fungal isolates. Top-line data from the Phase 3 ReSTORE trial is expected by year-end 2021, with a New Drug Application (NDA) filing anticipated in mid-2022.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, a biotechnology company focused on long-acting therapeutics, announced that CEO Jeffrey Stein will participate in two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a presentation available from 7:00 AM ET on September 13, 2021. The Cantor Global Healthcare Conference is scheduled for September 28, 2021, at 10:40 AM ET. Both presentations can be accessed on the company's website. Cidara is developing treatments for fungal and viral infections.
Cidara Therapeutics (NASDAQ: CDTX) is hosting a webinar on September 21, 2021, from 10am to 12pm ET, focusing on the Cloudbreak® platform and the commercial prospects for rezafungin.
Clinical experts will address the increasing risks of invasive fungal infections in cancer patients and discuss unmet needs in respiratory viral diseases.
The event will feature updates on rezafungin's late-stage development, and its potential role in treating candidemia and preventing infections in immunocompromised patients.
Cidara Therapeutics announced key management appointments, bringing in Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer, and Shane Ward as Chief Legal Officer and Corporate Secretary. Both bring over 20 years of biotech experience. The company is poised for significant milestones, including top-line data from the pivotal Phase 3 ReSTORE trial of its antifungal candidate, rezafungin, expected by year-end. Inducement awards were granted to Shah and Ward under the 2020 Inducement Incentive Plan, with options covering a total of 561,850 shares.